Amplia CEO and MD Dr Chris Burns commented: “We are delighted that Dr Lickliter is joining the team
at Amplia. It’s an exciting time for the Company as we near important data readouts for the ongoing
ACCENT Phase 2a trial and with the FOLFIRINOX combination Phase 1b/2a trial shortly to start. Jason’s
involvement and contributions as CMO will be critical to help guide our ongoing clinical activities.
Ann: Amplia Appoints Dr Jason Lickliter as Chief Medical Officer, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
-0.005(2.08%) |
Mkt cap ! $91.57M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 23.0¢ | $766.6K | 3.262M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 179879 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 402089 | 6 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |